Personalised Medicine in the Identification of Preclinical Cognitive Impairment. Development of a Predictive Risk Model

Launched by INSTITUTO DE SALUD CARLOS III · Oct 27, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how we can better predict early signs of cognitive impairment, which is a decline in thinking and memory skills, in people aged 55 to 70. Researchers want to collect and analyze a wide range of information about participants, including their medical history, lifestyle, and social factors, using advanced technology. The aim is to develop a model that helps identify individuals who might be at risk of cognitive issues before they become noticeable.

To be eligible for this study, participants need to be between 55 and 70 years old, living independently, and have no prior diagnosis of cognitive impairment. They should also have been connected to a primary care center in the study area within the last year. Participants will complete some questionnaires about their health and lifestyle, and they can expect to contribute to important research that could help identify cognitive issues sooner in the future. It's important to note that individuals with certain health conditions or those who are currently hospitalized may not be able to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Non-institutionalised subjects from the study locations.
• • Aged between 55 and 70 years, attached to the PC centres of the territories included in the study
• • Living history (at least one record in the last 12 months)
• • Without an established diagnosis of CI.
• Exclusion Criteria:
• • Participants with significant difficulties in completing self-reported questionnaires
• • Those in whom genetic or biological testing may be affected by an underlying genetic or health condition.
• • Underlying genetic or health condition.
• • Patients who are hospitalised or institutionalised during follow-up will be excluded.